https://www.imagine-eyes.com/wp-content/uploads/RP-banner-web-event-page.png
544
1596
contrib
https://www.imagine-eyes.com/wp-content/uploads/logo.svg
contrib2026-06-25 19:04:272026-06-29 20:08:44Retinitis Pigmentosa: Advanced imaging biomarkersOver a billion people suffer from diseases that impact the back of their eyes. Advanced opthalmic imaging open new avenues to better diagnose and treat these pathologies.
Imagine Eyes’ solutions enable examining patients’ retinas with an unprecedented level of detail – the cellular level – thanks to adaptive optics technology.
AO imaging lets you see what conventional retinal imaging cannot: damage at the level of individual cells, vascular wall remodeling, and other subclinical microlesions – directly in patients’ retinas.
For clinical research and retinal therapy development, this means new discoveries in disease mechanisms, and highly sensitive cellular biomarkers to de-risk and accelerate development programs.
Sensitive biomarkers for clinical research and trials
Cellular-scale Microvascular retinal assessments
rtx1™
The world’s most widely used AO imaging device







New Review Article on Retinal Vascular Remodeling Assessed with RTX1
Non-neovascular AMD: update on candidate AO biomarkers
Regenerative retinal therapy evaluated with adaptive optics imaging
Early atrophic changes in AMD captured by rtx1
Cone cells before/after macular hole surgery
Photoreceptor changes in diabetes: new findings published